Clinical Hurdles and Possible Solutions in the Implementation of Closed-Loop Control in Type 1 Diabetes Mellitus

From an engineering perspective, controlling blood glucose appears to be a fairly straightforward single input (glucose), single output (insulin) control problem. Unfortunately, mimicking Mother Nature turns out to be a complex endeavor. The primary hurdle in developing a useful, safe closed-loop control algorithm for an artificial pancreas is the time delays associated with current continuous glucose monitors and subcutaneously delivered insulins. This article will provide a brief history of the artificial pancreas, outline the main clinical hurdles restricting its current implementation, and list possible solutions for success.

[1]  E. Renard,et al.  A reduction in severe hypoglycaemia in type 1 diabetes in a randomized crossover study of continuous intraperitoneal compared with subcutaneous insulin infusion , 2009, Diabetes, obesity & metabolism.

[2]  D. Schade,et al.  Current status of portable insulin infusion devices , 1981, Diabetologia.

[3]  G. Pacini,et al.  Amylin: History and Overview , 1997, Diabetic medicine : a journal of the British Diabetic Association.

[4]  Howard Zisser,et al.  Automatic Detection of Stress States in Type 1 Diabetes Subjects in Ambulatory Conditions. , 2010, Industrial & engineering chemistry research.

[5]  A H Clemens,et al.  The development of Biostator, a Glucose Controlled Insulin Infusion System (GCIIS). , 1977, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[6]  W Zingg,et al.  Clinical Control of Diabetes by the Artificial Pancreas , 1974, Diabetes.

[7]  R E Gander,et al.  Comparison of Peripheral and Portal Routes of Insulin Infusion by a Computer-controlled Insulin Infusion System (Artificial Endocrine Pancreas) , 1976, Diabetes.

[8]  D. Dunger,et al.  Overnight closed-loop glucose control following consumption of alcohol in adults with type 1 diabetes , 2010 .

[9]  Aaron J. Kowalski,et al.  Can we really close the loop and how soon? Accelerating the availability of an artificial pancreas: a roadmap to better diabetes outcomes. , 2009, Diabetes technology & therapeutics.

[10]  Lutz Heinemann,et al.  Variability of insulin absorption and insulin action. , 2002, Diabetes technology & therapeutics.

[11]  C. C. Palerm,et al.  Closed-Loop Insulin Delivery Using a Subcutaneous Glucose Sensor and Intraperitoneal Insulin Delivery , 2009, Diabetes Care.

[12]  B. Sugarman,et al.  Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase. , 2009, Diabetes technology & therapeutics.

[13]  C H Best,et al.  Pancreatic Extracts in The Treatment of Diabetes Mellitus , 1956, Diabetes.

[14]  J. Leahy,et al.  Fully Automated Closed-Loop Insulin Delivery Versus Semiautomated Hybrid Control in Pediatric Patients With Type 1 Diabetes Using an Artificial Pancreas , 2008 .

[15]  Howard C. Zisser,et al.  Use of a Novel Fluorescent Glucose Sensor in Volunteer Subjects with Type 1 Diabetes Mellitus , 2011, Journal of diabetes science and technology.

[16]  A. Caumo,et al.  Peritoneal and subcutaneous absorption of insulin in type I diabetic subjects. , 1993, The Journal of clinical endocrinology and metabolism.

[17]  R. Hovorka.  Continuous glucose monitoring and closed‐loop systems , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[18]  K. Rave,et al.  Pharmacokinetics and linear exposure of AFRESA™ compared with the subcutaneous injection of regular human insulin , 2009, Diabetes, obesity & metabolism.

[19]  Eyal Dassau,et al.  Enhanced 911/Global Position System Wizard: A Telemedicine Application for the Prevention of Severe Hypoglycemia—Monitor, Alert, and Locate , 2009, Journal of diabetes science and technology.